Financials in USD. Standardized financial statements.
A compact view of how Pacira BioSciences, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $726.41M | $700.97M | $674.98M | $666.82M | $541.53M | $429.65M | $421.03M | $337.28M | $286.63M | $276.37M |
| Revenue Growth? | +3.6% | +3.9% | +1.2% | +23.1% | +26.0% | +2.0% | +24.8% | +17.7% | +3.7% | 0.0% |
| Cost of Revenue? | $149.75M | $170.43M | $184.67M | $199.29M | $140.25M | $117.33M | $106.71M | $86.84M | $87.92M | $110.10M |
| Gross Profit? | $576.66M | $530.54M | $490.31M | $467.53M | $401.28M | $312.32M | $314.31M | $250.43M | $198.72M | $166.27M |
| Gross Margin? | +79.4% | +75.7% | +72.6% | +70.1% | +74.1% | +72.7% | +74.7% | +74.3% | +69.3% | +60.2% |
| Operating Expenses? | $543.36M | $603.91M | $402.63M | $407.50M | $311.35M | $265.97M | $303.83M | $232.95M | $218.78M | $198.29M |
| Operating Income? | $33.30M | -$73.37M | $87.67M | $60.02M | $89.92M | $46.35M | $10.48M | $15.91M | -$24.94M | -$32.02M |
| EBITDA? | $122.50M | $29.12M | $154.59M | $140.38M | $113.95M | $63.51M | $30.75M | $33.05M | -$10.59M | -$17.86M |
| Income Before Tax | $16.87M | -$63.11M | $61.70M | $13.30M | $56.40M | $20.09M | -$10.75M | -$425,000 | -$42.47M | -$37.84M |
| Income Tax Expense | $9.84M | $36.45M | $19.75M | -$2.61M | $14.42M | -$125.43M | $268,000 | $46,000 | $140,000 | $105,000 |
| Net Income? | $7.03M | -$99.56M | $41.95M | $15.91M | $41.98M | $145.52M | -$11.02M | -$471,000 | -$42.61M | -$37.95M |
| EPS? | $0.16 | $-2.15 | $0.91 | $0.35 | $0.95 | $3.41 | $-0.27 | $-0.01 | $-1.07 | $-1.02 |
| Diluted EPS? | $0.16 | $-2.15 | $0.89 | $0.34 | $0.92 | $3.33 | $-0.27 | $-0.01 | $-1.07 | $-1.02 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality